ANA
LLUCH HERNANDEZ
EMÉRITO/A UNIVERSIDAD
Hospital Clínico Universitario Lozano Blesa
Zaragoza, EspañaPublicacións en colaboración con investigadores/as de Hospital Clínico Universitario Lozano Blesa (12)
2017
-
18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial
Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441
-
Critically short telomeres and toxicity of chemotherapy in early breast cancer
Oncotarget, Vol. 8, Núm. 13, pp. 21472-21482
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Preventive treatments for breast cancer: recent developments
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 257-263
2013
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)
Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447
2009
-
Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study
Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314
2008
-
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Annals of Oncology, Vol. 19, Núm. 6, pp. 1090-1096
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2005
-
Development of a questionnaire to measure health-related quality of life (HRQoL) in patients with bone metastases (BOMET-QoL)
Journal of Outcomes Research, Vol. 9, Núm. 15-27, pp. 15-27